Half Year 2026 TheraCryf PLC Earnings Call Transcript
Key Points
- TheraCryf PLC (LSE:TCF) has made significant progress with its lead asset, the orexin-1 antagonist, which is on track for regulatory submission by the end of next year.
- The company is highly capital efficient, with a cash runway extending to the end of 2026, placing it in the top 20% of European biotech companies in terms of cash runway.
- TheraCryf PLC has a strong patent portfolio, including recent patent grants in Korea, with global coverage expected soon.
- The company has a diversified portfolio with promising assets targeting CNS disorders, including a dopamine modulator for fatigue in multiple sclerosis.
- The management team is heavily invested in the company, aligning their interests with shareholders and demonstrating confidence in the company's future prospects.
- The company is still in the preclinical stage for its lead asset, which carries inherent risks and uncertainties.
- TheraCryf PLC's valuation does not yet reflect the potential value of its orexin-1 asset, which may be frustrating for investors.
- There is ongoing uncertainty regarding the resolution of a dispute with Stalicla, which could impact potential milestones and cash flow.
- The geopolitical climate, particularly in the US, poses challenges for securing non-dilutive grant funding for expansion into other disorders.
- The company faces competition from GLP-1 drugs in the treatment of binge eating disorder, although it believes its orexin-1 blocker offers a differentiated mechanism.
Good morning, and welcome to the TheraCryf Plc half results investor presentation. (Operator Instructions). The company may not be in a position to answer every question it receives during the meeting itself. However, the company can review your questions submitted today and publish responses where it is appropriate to do so. Before we begin, I would like to submit the following poll.
And I would now like to hand you over to our CEO, Huw Jones. Good morning to you.
Thanks, Alex, and good morning, everybody. Thanks for attending our half year report Investor Meet webinar. With me here in London is our Chair, Alastair, our CFO; Toni and our COO, Helen, we're very excited. We've come more handed because we're very excited about the progress we've made in a relatively short period on our now lead asset.
But before we start in earnest, we are a public company, we're AIM listed because the usual disclaimers will apply. So to remind you then, first, before we get to the news that
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
